Message

From: Reinhart, Roger [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=218AC2FB5AD8481BBE8FD68E3F0D1E1F-RREINHAR]
Sent: 4/22/2020 2:29:21 PM
To: Wilson, Jennifer [wilson.jenniferA@epa.gov]
CC: Rowsey, Kevin [rowsey.kevin@epa.gov]
Subject: RE: Bi-Weekly Sampling at Plant GAC Treatment

I agree with you on this. I believe Rick was just being careful before providing his approval for anything that appears to be backsliding. EPA has taken much criticism from several groups concerning its recent policy on allowances provided to industry due to the COVID-19 situation.

From: Wilson, Jennifer <wilson.jenniferA@epa.gov>
Sent: Wednesday, April 22, 2020 10:23 AM
To: Reinhart, Roger <Reinhart.Roger@epa.gov>
Cc: Rowsey, Kevin <rowsey.kevin@epa.gov>
Subject: RE: Bi-Weekly Sampling at Plant GAC Treatment

Enforcement confidential and deliberative. Do not release for FOIA or discovery.

Hi Roger,

Please let me know what Rick says. I don't really want to Ex. 5 Deliberative Process (DP)
Ex. 5 Deliberative Process (DP)

Thank you for informing Andrew. I appreciate it.

Have a good day,
Jenny

From: Reinhart, Roger <Reinhart.Roger@epa.gov>
Sent: Wednesday, April 22, 2020 9:12 AM
To: Wilson, Jennifer <wilson.jenniferA@epa.gov>
Cc: Rowsey, Kevin <rowsey.kevin@epa.gov>
Subject: RE: Bi-Weekly Sampling at Plant GAC Treatment

Thanks Jenny,

I forwarded the monitoring results to Rick Rogers who asked to review them - he has not gotten back to me yet. When he does I will inform Andrew Hartten of our position. However, I agree that Ex. 5 Deliberative Process (DP)
Ex. 5 Deliberative Process (DP)

From: Wilson, Jennifer <wilson.jenniferA@epa.gov>
Sent: Wednesday, April 22, 2020 10:04 AM
To: Reinhart, Roger <Reinhart.Roger@epa.gov>; Rowsey, Kevin <rowsey.kevin@epa.gov>
Subject: FW: Bi-Weekly Sampling at Plant GAC Treatment

Hi Roger and Kevin,

I looked at the attached results for GenX at Washington Works and Roger, I agree with what you said, Ex. 5 Deliberative Process (DP)

Ex. 5 Deliberative Process (DP)

Also, I was wondering if you two know what PFOA value Chemours uses as a carbon changeout requirement at Washington Works? Have we ever seen that? I am guessing they have a value after the lead bed?

Thank you,
Jenny

From: Hartten, Andrew S <Andrew.S.Hartten@chemours.com>
Sent: Monday, April 20, 2020 1:41 PM
To: Reinhart, Roger <Reinhart.Roger@epa.gov>; Wilson, Jennifer <wilson.jenniferA@epa.gov>
Cc: Parsons, Glennda <glennda.parsons@chemours.com>; Katherine Davis <katherine.l.davis@aecom.com>; Bjorn Cuento <bjorn.cuento@aecom.com>
Subject: Bi-Weekly Sampling at Plant GAC Treatment

Hello Roger and Jenny,

Back in early 2018 when there were many questions concerning HFPO-DA and the like, we began monitoring the plant GAC Treatment system bi-weekly (i.e., PFOA and HFPO-DA). We have now been doing that for 24 months and have built a considerable database, and have gone through several carbon change outs documenting excellent treatment results.

I just wanted you to know that in May that we plan to go back to the normal "monthly" sampling we are required to do under the WV DOH permit for the treatment system.

Let me know if you see problems with this. We are trying to trim un-necessary costs in these tough economic times.

Thanks.....Andrew

Andrew S. Hartten
Principal Project Manager-Corporate Remediation
+1 302 773 1289 o
Ex. 6 Personal Privacy (PP) m
The Chemours Company
1007 Market Street, #507-3
Wilmington, DE 19899



LinkedIn | Twitter | Chemours.com

<="" style="">
This communication is for use by the intended recipient and contains information that may be privileged, confidential or copyrighted under applicable law. If you are not the intended recipient, you are hereby formally notified that any use, copying or distribution of this e-mail, in whole or in part, is strictly prohibited. Please notify the sender by return e-mail and delete this e-mail from your system. Unless explicitly and conspicuously designated as "E-Contract Intended", this e-mail does not constitute a contract offer, a contract amendment, or an acceptance of a contract offer. This e-mail does not constitute a consent to the use of sender's contact information for direct marketing purposes or for transfers of data to third parties.

https://www.chemours.com/en/email-disclaimer